PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
Yonghui Sun(Tsinghua University), Yu Rao(Soochow University), Meng Zhao(Nanjing University of Information Science and Technology), Jinseok Hwang(Tsinghua University), Wanli Liu(Center for Life Sciences), Ning Ding(Nanjing University of Chinese Medicine), Yue Wu(Tsinghua University), Xingwang Zhao(Chongqing University), Yiqing Yang(Tsinghua University), Yuqin Song(Peking University), Hongying Gao(Tsinghua University)
Cited by 280
Related Papers
PROTACs: great opportunities for academia and industry
|Signal Transduction and Targeted Therapy|2019|627
PROTAC Technology: Opportunities and Challenges
|ACS Medicinal Chemistry Letters|2020|353
Chemistries of bifunctional PROTAC degraders
|Chemical Society Reviews|2022|270
A lever-like transduction pathway for long-distance chemical- and mechano-gating of the mechanosensitive Piezo1 channel
|Nature Communications|2018|268